You are here

ADA

Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist

Fierce Biotech

Mon, 06/10/19 - 09:39 am

type 2 diabetes

ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?

Fierce Pharma

Mon, 06/10/19 - 09:27 am

Insulin Patch Earns Spot in American Diabetes Association Guidelines for Diabetes Care

Xtalks

Thu, 05/30/19 - 05:31 pm

type 2 diabetes

Diabetes group nods to Vascepa, sending Amarin stock higher

Biopharma Dive

Thu, 03/28/19 - 07:59 pm

Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

NASDAQ.com

Tue, 06/26/18 - 09:47 am

type 2 diabetes

hypercholesterolemia

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Mon, 06/25/18 - 09:07 pm

ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis

Fierce Pharma

Mon, 06/25/18 - 09:06 pm

Boehringer Ingelheim

ADA preview: 5 things to watch in diabetes

BioPharma Dive

Sun, 06/11/17 - 09:30 am

Boehringer Ingelheim

PCSK9 inhibitors

Amgen Regeneron

ADA guidelines highlight new Jardiance label

BioPharma Dive

Mon, 12/19/16 - 11:39 am

Boehringer Ingelheim

Who Got The Most Buzz At The Diabetes Show?

Pharmalot

Wed, 06/13/12 - 12:05 pm

Bristol-Myers Squibb

Sanofi, Novo Nordisk, Amylin all tout diabetes treatments at ADA

Fierce Pharma

Mon, 06/11/12 - 01:17 pm

Research Presented at ADA Adds to the Clinical Evidence for Medtronic’s Sensor-Augmented Insulin Pump Therapy

Mon, 06/27/11 - 05:55 pm

ADA diabetes roundup: Is surgery the answer?

Fri, 06/24/11 - 11:18 pm

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

Yahoo

Tue, 06/9/09 - 07:43 am

Isis Pharmaceuticals

ADA trials boost Januvia, question costly meds

Fierce Pharma

Mon, 06/8/09 - 02:54 pm

Pages